Lexicon Pharmaceuticals Inc (LXRX) Stock AnalysisLXRXLexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lexicon Pharmaceuticals Inc (LXRX) is currently trading at $1.52, which is significantly below the analyst price target of $8, indicating a potential upside of over 400%. However, the stock has a very low RSI of 19.53, suggesting it is oversold, but it has also experienced a 25.85% decline over the past 20 days, indicating bearish momentum. The main risk is the company's negative earnings trend, with a net income loss of $31.77 million reported in Q2 2026, which raises concerns about its financial stability.

7 analysts cover LXRX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 4.03.